中国中药(00570)今日股价大跌,低开近15%,报3.25港元。这与公司早前宣布的私有化计划告吹直接相关。去年2月,中国中药曾公布其大股东国药集团有意以每股4.6港元的价格将公司私有化,但该计划因未获境外直接投资审批被终止。
国药集团未能在10月18日最后期限前获得所需批准,导致私有化计划无法继续推进。这个消息无疑严重打击了投资者信心,加之私有化溢价不复存在,直接引发了当日中国中药股价大幅下跌。
除了失去溢价机会,私有化计划失效还可能影响公司未来融资渠道,并加大了大股东控股的不确定性。长远来看,这将不利于中国中药未来业务发展。行业分析师普遍认为,中药股短期股价有望在低位盘整。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.